The Primary Hepatocytes market was valued at US$ 213.8 Mn in 2021 and is projected to expand at a CAGR of 6.6% over the forecast period (2022-2032).
Primary Hepatocytes Market Analysis
One of the main factors driving the growth of the primary hepatocytes market is the rising frequency of chronic diseases like cancer, the quick expansion of the biopharmaceutical sectors, and the growing emphasis on R&D. The market is also expanding as a result of improvements in cancer research and the infrastructure supporting healthcare.
Due to the increased incidence of cancer worldwide, it is anticipated that the use of primary hepatocytes for drug delivery and toxicity tests will significantly expand. Over the course of the projection period, it is expected that rising rates of a number of malignancies, including liver, lung, and breast cancer, will drive revenue growth in the worldwide primary hepatocytes market.
Because doctors are becoming more aware of the need, the demand for medication therapy for cancer patients has surged recently. As a result, there is an increase in primary hepatocyte research, which benefits the industry.
Click on the link for a sample report:https://www.persistencemarketresearch.com/samples/32880
Key Market Study Conclusions
- By product, by the end of 2032, cryopreserved suspension hepatocytes will possess a 37.5% market value share.
- With more than 60% of the market, the human primary hepatocytes category will rule the world in 2022.
- In 2022, it’s anticipated that cell viability assays would account for over 1/4 of total revenue.
- Biopharmaceutical businesses will hold over 50% of the global market share in 2022.
- By the end of 2032, North America is anticipated to have a share of 30.4% of the global market.
Marketplace rivalry
Leading companies, like LifeNet Health and Thermo Fisher Scientific, among others, are focusing on business development to increase their market share and add new product lines to their existing product portfolios.
- To support its growth in the burgeoning biologics sector, Thermo Fisher partnered with CSL, a major worldwide biotechnology business, in March 2020.
- Thermo Fisher announced the opening of a cell therapy development and management centre in September 2020, investing around US$45 million in it to advance its cell therapy platform and facilitate a seamless transition from R&D to process development.
- In order to provide R&D and tissue-engineering services, LifeNet Health constructed a new facility in San Diego, California, in 2019.
Click on the link for a customized report:https://www.persistencemarketresearch.com/request-customization/32880
What Is Covered in the Report?
In its most recent analysis, Persistence Market Research presents a historical demand assessment for the years 2017–2021 and estimates for 2022–2032, providing a unique viewpoint and practical insights on the primary hepatocytes market.
The research project is based on the following factors: product (cryopreserved suspension hepatocytes, fresh suspension hepatocytes, 3D (spheroid) hepatocytes, expanded hepatocytes (plateable), and uncharacterized hepatocytes), species (humans, rats, mice, dogs, monkeys, horses, and others), application or assay (cell viability assays, cytochrome enzyme activity, high content cytotoxicity.
Frequently asked questions:
- Which company has the highest market share in Primary Hepatocytes Market?
- What are the driving factors of the Primary Hepatocytes Market?
- What is the growth rate of the Primary Hepatocytes Market in the forecasted year?
- What are the restraining factors of the Primary Hepatocytes Market ?
- Which region has the highest market share of the Primary Hepatocytes Market?
- What was the impact of the Covid-19 pandemic on the Primary Hepatocytes Market?
About us:
Persistence Market Research, as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]